Novo Nordisk A/S Sponsored ADR (NVO)
Imperial College spin-out Myricx Bio lands £90m of new investment
An Imperial College spin-out has landed £90 million in Series-A funding backed by heavyweight investors, including an offshoot of the British Business Bank (BBB). Myricx Bio, the recipient of this funding, is at the forefront of developing innovative cancer treatments.
Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector
Danish drugmaker Novo Nordisk has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organisations in Britain amounting to about 7.8 million pounds ($9.97 million) between 2020 and 2022.
Is It Too Late to Buy Novo Nordisk Stock?
Novo Nordisk's valuation is high, and the U.S. patent for semaglutide expires in early 2026. However, the drugmaker has a promising pipeline that could drive growth for years to come.
Novo Nordisk shares drop as study links drugs to vision loss
Novo Nordisk (NYSE:NVO) shares have dropped by close to 4% this week, shedding more than £350 billion from its market cap, after a study suggested there may be a link between its blockbuster weight loss drugs Wegovy and Ozempic and vision loss. Those who have been prescribed the weight-loss injection are at a higher risk of developing an eye condition linked to blindness, the study said.
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Novo Nordisk shares shrug off concerns over study linking weight loss drugs to rare eye condition
Blockbuster weight loss drugs such as Wegovy and Ozempic may be associated with a rare eye condition, according to a new study released Wednesday. A Novo Nordisk spokesperson said there were "key methodological limitations" to the study.
Using Ozempic Or Wegovy Could Raise Risk For Rare Form Of Blindness, Study Suggests
People who use Ozempic or Wegovy for treating obesity or Type 2 diabetes may have an increased risk of developing a rare form of blindness, according to a study published Wednesday in the journal JAMA Network, which Novo Nordisk has criticized for being insufficient.
Wegovy, Ozempic linked with sight-threatening eye disorder in study
Patients using Novo Nordisk's wildly popular weigh-loss drug Wegovy and its similar medicines for type 2 diabetes may be at increased risk for a sight-threatening eye condition, according to data from a study published on Wednesday.
Why Novo Nordisk Stock Is Slipping Today
A USA Today op-ed from President Joe Biden and Sen. Bernie Sanders criticized Novo Nordisk.
How To Pick Top Pharma Stocks: Novo Nordisk And More
This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of the investment attractiveness of this or that company. The rest of the article will contain an analysis of Novo Nordisk, which is a leader in the fast-growing anti-obesity medicines market.
Novo Nordisk must cut prices of weight-loss drug, Biden says in USA Today piece
U.S. President Joe Biden and Senator Bernie Sanders called on Novo Nordisk to cut prices of its Ozempic and Wegovy drugs for weight loss and diabetes, in an opinion piece by them published in USA Today on Tuesday.
Novo Nordisk steps up ad spend to keep the weight-loss crown
Novo Nordisk (NYSE:NVO) appears to be taking a no-holds-barred approach to becoming the number one weight-loss drug in the US after it emerged that an ad for one of its key products was viewed nearly 2 billion times between June 3 and June 25, making it the third most-watched commercial during that period. The Wall Street Journal, citing iSpot.tv, reported the Wegovy ad, titled "Discover the Power", was shown 6,271 times and cost an estimated $42 million in national airtime.
